Hematologic Malignancy
Acute Biphenotypic Leukemia
CI-CAN-00007129Explore in graph →
Hematologic14 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007129Explore in graph →
Clinical trials
41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02529813 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02044796 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 199 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 5, 2023source: clinicaltrials